hit
counter
News

<< Return

Imperial Health Seeks Participants for Cardiovascular Disease Research Study - Friday, November 3, 2017

Imperial Health is serving as one of 600 sites for a global cardiovascular outcomes trial to assess the safety and effectiveness of bempedoic acid, an investigational medicine, on the occurrence of major cardiovascular events, such as heart attacks or strokes, in patients with, or at a high risk for, cardiovascular disease.  This research is taking place under the direction of cardiologist Richard Gilmore, MD, with Imperial Health Cardiovascular Specialists.

The CLEAR Outcomes study, which stands for Cholesterol Lowering via BEmpedoic Acid-inhibiting Regimen, is a double-blind, placebo-controlled study Ė meaning neither the participant nor the investigator will know who is receiving a treatment. This is a common mechanism employed to prevent bias in research results.

First and foremost, candidates must have or be at high risk for cardiovascular disease. Specifically, this research study focuses on patients who are unable to take statin medications for the lowering of cholesterol due to side effects. Popular statin medications include Lipitor, Lescol, Livalo, Pravachol, Zocor and their generic counterparts. Participant qualifications include, but are not limited to: being at least 18 years of age, having a history of or a high risk for cardiovascular disease and being statin intolerant, meaning you have not been able to tolerate two or more statin medications, and other study criteria.

Qualified participants will receive all study medication and study-related care from a dedicated team of medical staff at no cost, and health insurance is not required to participate.

Patients who think they may qualify for and are interested in the CLEAR Outcomes study should contact Imperial Healthís Research Department at (337) 312-8412 or (337)312-8405.

Imperial Health is the regionís largest multi-specialty medical group. For over 25 years, the groupís Research Department has been conducting groundbreaking research led by members of Imperial Healthís medical staff. To learn more about Imperial Health, visit www.imperialhealth.com.

Esperion Therapeutics, Inc., the lipid management company behind Bempedoic Acid, is an Ann Arbor, Michigan-based company passionately committed to developing and commercializing non-statin medications for the lowering of cholesterol. For more information on Esperion, visit www.esperion.com.

 

 

###

 

 

 


 

© Copyright 2017, Imperial Health. All rights reserved.